Mavodelpar

N/A

Report date: 2025/03/14 09:31:58
NME

Base Information

Drug NameMavodelpar
Drug Alias Namemavodelpar sodiumHPP-593REN-001NN-0606
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor delta agonistsPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptorPeroxisome proliferator-activated receptor delta
Therapy Area/IndicationsLipid Metabolism DisordersGlycogen Storage Disease Type VMuscular Atrophy +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovo Nordisk A/SVtv Therapeutics LlcReneo Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesReneo PharmaReneo Pharma Ltd
Inactive CompaniesHigh Point Pharmaceuticals Llc
Active IndicationsLipid Metabolism DisordersGlycogen Storage Disease Type VMitochondrial Myopathies
Inactive IndicationsMuscular AtrophyHypokinesia

Other Information

ATC CodeN/A
Related LinksN/A